Genitourinary Cancer
Information
- Disease name
- Genitourinary Cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02735252 | Active, not recruiting | N/A | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | May 25, 2016 | July 31, 2025 |
| NCT01505400 | Active, not recruiting | Integrated Molecular Profiling in Advanced Cancers Trial | February 2012 | January 2025 | |
| NCT03333616 | Active, not recruiting | Phase 2 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | December 28, 2017 | May 31, 2025 |
| NCT06168825 | Active, not recruiting | Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention | January 17, 2024 | December 31, 2024 | |
| NCT03794635 | Active, not recruiting | N/A | An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer | December 20, 2018 | December 2024 |
| NCT02583815 | Completed | Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP) | August 2015 | September 15, 2017 | |
| NCT01375699 | Completed | Phase 1 | Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | August 11, 2011 | January 19, 2018 |
| NCT01433302 | Completed | Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass | March 2012 | March 2014 | |
| NCT03887091 | Completed | N/A | Personal Web Page In Clinical Trial Participant Education | July 21, 2014 | May 2019 |
| NCT04020978 | Completed | N/A | Parametric PET of Genitourinary Cancer | July 16, 2019 | December 15, 2023 |
| NCT02060370 | Completed | Phase 2 | Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | August 2014 | January 2, 2019 |
| NCT02140463 | Completed | Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial) | February 2014 | October 29, 2019 | |
| NCT02222259 | Completed | N/A | A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients | September 2014 | August 2016 |
| NCT05629065 | Enrolling by invitation | N/A | Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC) | November 28, 2022 | December 31, 2025 |
| NCT06253520 | Recruiting | Phase 1 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | May 16, 2024 | June 15, 2033 |
| NCT02906943 | Recruiting | Ontario-wide Cancer TArgeted Nucleic Acid Evaluation | August 2016 | August 2026 | |
| NCT03740503 | Recruiting | Genomic Investigation of Unusual Responders | November 1, 2013 | November 2024 | |
| NCT04235777 | Recruiting | Phase 1 | Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | July 13, 2020 | December 1, 2024 |
| NCT04273061 | Recruiting | Phase 2 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | June 17, 2020 | October 2026 |
| NCT04354064 | Recruiting | Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | May 29, 2019 | December 31, 2025 | |
| NCT04761107 | Recruiting | Impact of COVID-19 on GU Disease | February 18, 2021 | February 2026 | |
| NCT04923178 | Recruiting | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies | October 24, 2022 | December 1, 2042 | |
| NCT05837598 | Recruiting | N/A | Adapting the Tumor Board Model for Mental Illness and Cancer | May 31, 2023 | May 31, 2024 |
| NCT03480152 | Terminated | Phase 1/Phase 2 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | May 18, 2018 | November 5, 2019 |
| NCT00147238 | Terminated | N/A | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast | July 2005 | January 2007 |